Rezera (formerly NodThera)
Rezera is a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3 to address inflammatory drivers of cardiovascular and neurologic diseases driven by the NLRP3 inflammation pathway. Rezera is headquartered in Boston, Massachusetts, with an R&D base in Cambridge, UK.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Live
Website
www.nodthera.com
Related News
Rezera Announces Ruvonoflast Met its Primary Inflammation Endpoint and Demonstrated Favorable Safety Profile in RESOLVE-1 Phase 2 Clinical Trial
NodThera Announces the Publication and Presentation of Cardiometabolic Clinical Data Supporting the Potential of Ruvonoflast to Treat Inflammation at the Source
NodThera appoints Geoff McDonough as CEO
NodThera says NLRP3 inhibitor reverses neuroinflammation in Parkinson's
NodThera doses first patients in Phase 2 obesity trial
NodThera's NT-0796 enhances weight loss with GLP-1
NodThera announces appointment of Greg Chow as Chief Financial and Business Officer
NodThera meets primary endpoint in Phase 1b/2a trial
NodThera announces appointment of Daniel Swisher as Chief Executive Officer
NodThera’s NLRP3 inhibitor NT-0796 reverses neuroinflammation in Parkinson’s disease phase Ib/IIa trial
NodThera publishes preclinical data on NLRP3 inhibitors in obesity
NodThera is first to demonstrate reduction in neuroinflammation in the clinic with brain penetrant NLRP3 inflammasome inhibitor
NodThera announces positive Phase 1 study readouts for the NLRP3 inflammasome inhibitors NT-0796 and NT-0249
NodThera announces clinical progress for lead NLRP3 inflammasome inhibitors and candidate selection of novel brain-penetrant compound
NodThera Announces Close of $55 Million Series B Financing
NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board
NodThera secures £28 million ($40 million) Series A Financing
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.